ECC: Nivolumab, Cabozantinib bring long overdue options to advanced kidney cancer

VIENNA – The immune checkpoint inhibitor nivolumab extended overall survival by 5.4 months compared with standard therapy in patients with advanced kidney cancer in the phase III CheckMate 025...